Dataset Information


Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.

ABSTRACT: Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentially predictive of clinical outcome. The aim of this study was to assess the concordance of reported PD-L1 IHC assays and investigate factors influencing variability. Consecutive sections from 20 non-small cell lung cancers (NSCLCs) comprising resection, core biopsy, cytology and pleural fluid samples underwent IHC with 5 different antibody/autostainer combinations: 22C3/Link48, 28-8/BOND-MAX, E1L3N/BOND-MAX, SP142/BenchMark and SP263/BenchMark. PD-L1 RNA levels were assessed using RNAscope. The frequency of positive cases using scoring thresholds from clinical trials was 72%, 33%, 61%, 56%, and 33% for the 5 IHC protocols respectively, and 33% for RNAscope. Pairwise agreement on the classification of cases as positive or negative for PD-L1 expression ranged from 61%-94%. On a continuous scale, the lowest correlation was between 28-8/BOND-MAX and SP142/BenchMark (R2=0.25) and highest was between 22C3/Link48 and E1L3N/BOND-MAX (R2=0.71). When cases were ordered according to tumor cell (TC)%, a similar ranking of cases across IHC protocols could be observed, albeit with different quanta and limits of detection. Single-slide OPAL 7-color fluorescence IHC analysis revealed a high degree of co-localization of staining from the 5 PD-L1 antibodies. Using SP142 antibody in a BOND-MAX protocol led to increased TC% quanta, while retaining a similar ranking of samples according to TC%. The results of this study highlight tumor PD-L1 status can vary significantly according to IHC protocol. Protocol-dependent staining intensities and nominated thresholds for positivity contribute to this variability, while the antibody used appears to be less of a factor.


PROVIDER: S-EPMC5805519 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5650234 | BioStudies
2017-01-01 | S-EPMC5552229 | BioStudies
2020-01-01 | S-EPMC7280177 | BioStudies
2019-01-01 | S-EPMC6455756 | BioStudies
2018-01-01 | S-EPMC6249875 | BioStudies
2020-01-01 | S-EPMC6920558 | BioStudies
2018-01-01 | S-EPMC6750743 | BioStudies
2016-01-01 | S-EPMC4941982 | BioStudies
2017-01-01 | S-EPMC6175606 | BioStudies
2019-01-01 | S-EPMC6720992 | BioStudies